2017 Mechanisms & Models of Cancer, the Salk Institute, USA. “NUAK1 protects colorectal tumours from oxidative stress.”
2017 Genes & Cancer, Cambridge, UK. “The AMPK-related kinase NUAK1 protects colorectal cancer from oxidative stress.”
2016 Arbeitsgemeinschaft Internistische Onkologie 8th International Symposium, Berlin, Germany. “NUAK1 protects colorectal cancer from oxidative stress.”
2016 Beatson Institute Annual Conference, Glasgow, UK. “The ERBB network facilitates KRAS driven lung cancer.”
2015 CRUK Lung Cancer Centre of Excellence Conference, Manchester, UK. “KRas mutant NSCLC retains a requirement for signal transduction through EGFR-family receptors.”
2015 Cancer Metabolism Conference, San Francisco, USA. “The AMPK related kinase NUAK1 is a target for treatment of Colorectal Cancer.”
2015 DACH Retreat, Obergurgl, Austria. "MYC is insufficient for tumour initiation in the lung even in the absence of functional p53."
2014 International Society for Transgenic Technologies, Edinburgh, UK. "Temporally tractable systems for interrogating tumour progression in vivo."
2014 CRUK Beatson Institute Annual Conference, Glasgow, UK. "Deletion of the AMPK related kinase Nuak1/Ark5 prevents KRas accelerated Colon Cancer." Co-Organiser
2018 McGill University, Canada. By invitation.
2018 Imperial College London. "Dangerous Liaisons between MYC and NUAK1”
2017 Queens University, Belfast, Northern Ireland. “Translatable insights into lung cancer progression from GE mouse models.”
2017 University of Tubingen, Germany. “Exploiting Metabolic stress to treat Cancer.”
2017 National University Ireland, Galway. “Targeting MYC-induced metabolic stress in Cancer.”
2017 MRC Toxicology Centre, Leicester, UK. “Phenotypic evolution of a GEMM model reveals a druggable requirement for ERBB in KRAS-driven lung cancer.”
2017 University of Salamanca, Spain. “Phenotypic evolution of a GEMM model reveals a requirement for the ERBB network in KRAS-driven lung cancer.”
2016 University College London, Cancer Institute, UK. “Phenotypic evolution of a GEMM model reveals an unexpected role for ERBB in KRAS-driven lung cancer.”
2016 CRUK Oxford Cancer Center, UK. “Phenotypic evolution of a mouse model exposes therapeutic opportunities in Kras mutant NSCLC.”
2015 CRUK Edinburgh Cancer Centre. "Disentangling MYC from the ARF-p53 axis."
2015 University of British Columbia, Prostate Cancer Center, Vancouver, Canada. "Bim, not Arf, mediates MYC induced apoptosis in multiple tissues."
2014 University of Cambridge, England. "Undermining Myc: Mitochondria hold the key."